INDV

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.79
Percentage change 5.66	%

Peers: JNJ VRTX PFE ABBV BMY GILD LLY BIIB TEVA NBIX

| Held by: IWM IWO IWN RSSL IWV UWM URTY OMFS IBBQ BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.23	Insider Own	11.89%	Shs Outstand	125.00M	Perf Week	5.66%
Market Cap	1.84B	Forward P/E	10.22	EPS next Y	1.44	Insider Trans	0.00%	Shs Float	109.93M	Perf Month	18.78%
Enterprise Value	1.84B	PEG	-	EPS next Q	0.25	Inst Own	86.19%	Short Float	2.84%	Perf Quarter	54.18%
Income	-36.00M	P/S	1.57	EPS this Y	-23.99%	Inst Trans	21.74%	Short Ratio	2.30	Perf Half Y	22.94%
Sales	1.17B	P/B	-	EPS next Y	14.31%	ROA	-2.55%	Short Interest	3.13M	Perf YTD	18.58%
Book/sh	-2.28	P/C	4.93	EPS next 5Y	1.29%	ROE	-	52W High	16.24 -9.24%	Perf Year	-10.61%
Cash/sh	2.99	P/FCF	13.72	EPS past 3/5Y	-77.99% -56.08%	ROIC	-64.29%	52W Low	7.33 101.09%	Perf 3Y	38.40%
Dividend Est.	-	EV/EBITDA	6.00	Sales past 3/5Y	14.52% 8.64%	Gross Margin	82.82%	Volatility	3.50% 3.98%	Perf 5Y	6.89%
Dividend TTM	-	EV/Sales	1.57	EPS Y/Y TTM	-640.24%	Oper. Margin	24.02%	ATR (14)	0.53	Perf 10Y	-
Dividend Ex-Date	Jun 16, 2016	Quick Ratio	0.72	Sales Y/Y TTM	4.09%	Profit Margin	-3.08%	RSI (14)	70.84	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.88	EPS Q/Q	10.98%	SMA20	7.24%	Beta	1.14	Target Price	16.78
Payout	0.00%	Debt/Eq	-	Sales Q/Q	-6.34%	SMA50	20.66%	Rel Volume	2.13	Prev Close	13.95
Employees	1051	LT Debt/Eq	-	Earnings	Apr 24 BMO	SMA200	37.37%	Avg Volume	1.36M	Price	14.74
IPO	Dec 29, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	75.74% 10.77%	Trades		Volume	2,834,369	Change	5.66%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-25	Initiated	Rodman & Renshaw	Buy	$16
Jul-23-24	Initiated	Piper Sandler	Overweight	$22
Apr-03-24	Initiated	Craig Hallum	Buy	$37
Jul-13-23	Initiated	Northland Capital	Outperform	$35

Jun-30-25 07:00AM	Indivior Announces Inclusion in the U.S. Russell 2000 and 3000 Indexes (PR Newswire) +5.66%
Jun-27-25 05:45PM	IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Jun-24-25 04:12PM	Indivior Appoints Tony Kingsley to the Board of Directors (PR Newswire)
02:07PM	Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last? (Zacks)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
07:56AM	Loading…
07:56AM	RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains? (Zacks)
Jun-20-25 03:01AM	Addex Therapeutics Ltd (ADXN) Q1 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Jun-19-25 09:00AM	Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users (PR Newswire)
Jun-05-25 05:08AM	Wise Plans to Shift Main Listing to US in Latest London Loss (Bloomberg)
Jun-02-25 05:24AM	FTSE pharma giant joins London stock market exodus (The Telegraph)
02:00AM	Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained (PR Newswire)
May-27-25 08:30AM	Indivior Announces Patrick Barry as Chief Commercial Officer (PR Newswire) +5.02%
May-13-25 10:00AM	Indivior to Participate in Upcoming Investor Events (PR Newswire)
May-01-25 10:27AM	New Study Highlights Monthly SUBLOCADE as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy (PR Newswire)
Apr-28-25 12:12PM	Indivior: Trying To Break Addiction (Seeking Alpha)
10:45AM	Loading…
Apr-24-25 10:45AM	Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript (Seeking Alpha) +13.86%
07:05AM	Indivior PLC (INDV) Q1 Earnings and Revenues Beat Estimates (Zacks)
03:58AM	Indivior Q1 Net Income Declines; Net Revenue Down 6% (RTT News)
02:00AM	Indivior Announces Q1 2025 Financial Results (PR Newswire)
Apr-02-25 04:12AM	Indivior: A Complicated Story Of Both Declining Revenue And Strong Financials (Seeking Alpha)
Mar-31-25 07:51PM	Is Indivior PLC (INDV) the Best Stock to Buy According to Howard Marks' Oaktree Capital Management? (Insider Monkey)
Mar-27-25 05:35PM	Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Mar-04-25 08:40AM	Indivior Announces Further Changes to Board of Directors (PR Newswire) +5.76%
Mar-02-25 06:36PM	Is Indivior PLC (INDV) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-27-25 02:00AM	Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer (PR Newswire)
Feb-24-25 02:00AM	Indivior Announces FDA Approval of Label Changes for SUBLOCADE (buprenorphine extended-release) Injection (PR Newswire)
Feb-21-25 02:05AM	Indivior PLC (INDV) (Q4 2024) Earnings Call Highlights: Strong SUBLOCADE Growth and Strategic ... (GuruFocus.com) -6.01%
Feb-20-25 02:13PM	European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat (Benzinga) -17.60%
09:11AM	Earnings To Watch: Indivior PLC (INDV) Reports Q4 2024 Result (GuruFocus.com)
07:05AM	Indivior PLC (INDV) Q4 Earnings Meet Estimates (Zacks)
02:00AM	Loading…
02:00AM	Indivior Announces FY and Q4 2024 Financial Results (PR Newswire)
Feb-13-25 10:01AM	Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-12-25 02:00AM	Indivior Statement RE: Delayed FDA Approval of SUBLOCADE Label Changes (PR Newswire)
Jan-31-25 08:33AM	Heres Summers Value Partners Investment Thesis for Indivior (INDV) (Insider Monkey)
Nov-23-24 02:01AM	Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com)
Nov-19-24 12:52PM	Rapid Initiation with Once-monthly SUBLOCADE Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024 (PR Newswire)
Nov-07-24 02:24PM	Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior (PR Newswire) +16.34%
Oct-30-24 12:30PM	Indivior Highlights Growing Body of Data on SUBLOCADE (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month (PR Newswire)
Oct-25-24 03:07AM	Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Competitive ... (GuruFocus.com)
Oct-24-24 07:05AM	Indivior PLC (INDV) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
02:00AM	Indivior Announces Q3 2024 Financial Results (PR Newswire)
Oct-23-24 09:09AM	Indivior PLC (INDV) Q3 2024 Earnings Report Preview: What to Expect (GuruFocus.com)
Oct-17-24 05:03PM	Two Seas Capital LP Increases Stake in Indivior PLC (GuruFocus.com) +5.53%
Oct-12-24 08:35AM	Indivior price target lowered to $16 from $20 at Craig-Hallum (TipRanks)
Oct-11-24 03:00AM	Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ... (GuruFocus.com) -6.52%
Oct-10-24 09:28AM	Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details (Benzinga) -15.47%
07:00AM	Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion (PR Newswire)
Oct-07-24 11:30AM	Indivior's SUBLOCADE Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review (PR Newswire)
Oct-01-24 03:00AM	Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ... (GuruFocus.com)
Sep-23-24 02:00PM	Top 3 Health Care Stocks That May Explode This Month (Benzinga)
Sep-17-24 08:30AM	Indivior PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INDV (PR Newswire)
Sep-13-24 05:45AM	Indivior PLC Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights - INDV (PR Newswire)
Sep-11-24 08:15AM	Indivior PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INDV (PR Newswire)
Sep-06-24 05:45AM	Shareholders of Indivior PLC Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights - INDV (PR Newswire) -6.67%
Sep-04-24 02:00AM	Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder (PR Newswire)
Aug-27-24 08:48AM	Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder (Benzinga)
Aug-26-24 10:30AM	Indivior Announces BARDA's First Order of OPVEE to Combat Opioids and Aid in National Preparedness (PR Newswire)
Aug-08-24 12:38PM	Shareholders of Indivior PLC Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights INDV (GlobeNewswire)
Jul-26-24 10:44AM	Indivior reaches $86 million opioid settlement with 16 US states (Reuters)
Jul-25-24 07:05AM	Indivior PLC (INDV) Q2 Earnings and Revenues Beat Estimates (Zacks) +20.31%
02:10AM	Indivior Announces a New $100 Million Share Repurchase Program; New Program will be Executed Over an Accelerated Time Frame (PR Newswire)
02:00AM	Indivior Announces Q2 2024 Financial Results (PR Newswire)
Jul-18-24 10:01AM	Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-10-24 12:57PM	Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View (Zacks)
Jul-09-24 08:25AM	Why Is Indivior (INDV) Stock Down 37% Today? (InvestorPlace) -33.57%
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
02:00AM	Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT (PR Newswire)
Jul-03-24 02:39PM	Indivior CEO Expects Ongoing U.S. Opioid Crisis to Drive Sales Growth (The Wall Street Journal)
Jun-18-24 03:40PM	Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Cardiac Arrest (PR Newswire)
Jun-10-24 02:30PM	Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder (PR Newswire)
May-24-24 09:06AM	Indivior CEO Mark Crossley on combatting the opioid crisis with new drugs (CNBC TV)
May-23-24 07:02AM	Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance (PR Newswire)
Apr-26-24 01:01PM	Indivior PLC (INDV) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges with ... (GuruFocus.com)
Apr-25-24 07:53AM	INDV Stock Earnings: Indivior Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -8.29%
07:05AM	Indivior PLC (INDV) Q1 Earnings and Revenues Lag Estimates (Zacks)
04:38AM	UPDATE 1-UK-listed drugmaker Indivior seeks shareholder nod for US listing (Reuters)
03:48AM	Drugmaker Indivior to seek shareholder nod on shifting primary listing to US (Reuters)
03:44AM	Indivior Confirms Plan to Switch Listing From London to New York (Bloomberg)
02:00AM	Indivior Announces Q1 2024 Financial Results (PR Newswire)
Apr-04-24 09:27AM	Indivior (INDV) Surges 5.6%: Is This an Indication of Further Gains? (Zacks)
Mar-19-24 09:55AM	Indivior PLC (INDV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-11-24 02:43PM	Indivior Announces Publication Demonstrating that OPVEE (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone (PR Newswire)
Mar-07-24 11:56AM	Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 02:02AM	Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation (PR Newswire)
Feb-23-24 06:54AM	Health Care Roundup: Market Talk (The Wall Street Journal)
Feb-22-24 06:02AM	London Risks Losing Another Major Company to New York Stock Exchange (Bloomberg) +21.71%
05:21AM	Fresh blow for London market as drug maker joins exodus to New York (The Telegraph)
03:21AM	UPDATE 2-Drugmaker Indivior consults on moving primary listing from London to US (Reuters)
02:59AM	Indivior plans shifting primary listing to U.S. (Reuters)
02:00AM	Indivior Announces Q4 / FY 2023 Financial Results (PR Newswire)
Nov-13-23 09:35AM	Indivior PLC (INDV) Loses -17.71% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-09-23 07:15AM	Indivior PLC (INDV) Tops Q3 Earnings and Revenue Estimates (Zacks) -5.47%
02:05AM	Indivior Announces Q3 2023 Financial Results (PR Newswire)
Oct-23-23 11:35AM	Unveiling Indivior PLC (INDV)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com) +5.91%
02:36AM	Indivior to pay $385 million to end final Suboxone monopoly lawsuits (Reuters)
02:21AM	UPDATE 2-Indivior to pay $385 mln to end final Suboxone monopoly lawsuits (Reuters)
Oct-11-23 04:20PM	Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals (PR Newswire)
Oct-02-23 11:50AM	Indivior PLC (INDV): Unveiling Its Market Value (GuruFocus.com) -5.20%
Sep-26-23 02:30PM	Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada (PR Newswire)
Sep-25-23 11:53AM	Unveiling Indivior PLC (INDV)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Indivior Plc

Upgrade your FINVIZ experience